Organization
Tokyo, Japan
11 abstracts
Abstract
Acquired gene alteration patterns and post-progression survival: PARADIGM study analysis.Org: National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, Disaster Medical Center, Tokyo, Japan, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations.Org: Memorial Sloan Kettering Cancer Center, New York, NY, Institut Gustave Roussy, Villejuif, France, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan,
Abstract
Development of an artificial intelligence algorithm for adjuvant chemotherapy based on a nationwide registry of patients with gastric cancer by the Japanese Gastric Cancer Association (JGCA).Org: National Center for Global Health and Medicine, Tokyo, Japan, Healthcare & Life Sciences Services, IBM Japan, Ltd., Japan Medical Association Research Institute,
Abstract
Novel deep learning–based prognostic prediction model for colorectal cancer using hematoxylin and eosin–stained whole slide images.Org: Biomy Inc., Tokyo, Japan, Akita University Graduate School of Medicine, Akita, Japan, Keio University School of Medicine,
Abstract
Impact of patient travel time on disparities in precision oncology clinical trials.Org: Department of Experimental Therapeutics, National Cancer Center Hospital East, National Cancer Center Hospital East, Kashiwa, Japan, Tokyo, Japan,
Abstract
Progress report of a cross-organ and biomarker-based platform study: BELIEVE trial NCCH1901.Org: National Cancer Center Hospital East, Kashiwa, Japan, Chuo-Ku, Japan, Department of Laboratory Medicine and Pathology, University of Washington, Tokyo, Japan, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China,
Abstract
Analytical and clinical validation of Oncomine Dx Target (ODxT) test and local testing for identifying patients with HER2 (ERBB2)-mutant (HER2m) non–small-cell lung cancer (NSCLC) for treatment with trastuzumab deruxtecan (T-DXd) in DESTINY-Lung01/02 (DL-01/02).Org: Memorial Sloan Kettering Cancer Center, New York, NY, Netherlands Cancer Institute, Amsterdam, Netherlands, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Early changes of PSMA PET signal after initiation of androgen receptor signaling inhibitors in mCRPC: An international multicenter retrospective study.Org: Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, UCLA Department of Medicine, Division of Nuclear Medicine,
Abstract
Anemia in patients aged ≥75 years with metastatic clear cell renal cell carcinoma: An important IMDC prognostic factor for systemic therapy.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Keio University School of Medicine, Tokyo, Japan,
Abstract
APOPTOSIS-INDUCING EFFECT OF ANTI-FAS ANTIBODY R-125224 IN SYNOVIAL TISSUE-INFILTRATING LYMPHOCYTES AND SCID-HUPBL MODELOrg: Biological Research Laboratories, Sankyo Co., Ltd., Tokyo, Japan,
Abstract
BEZAFITRATE FOR METHOTOREXATE-INDUCED ACUTE LIVER INJUR\Y Org: Center for Rheumatology and Joint Surgery, Kawakita General Hospital, Tokyo, Japan,